https://www.selleckchem.com/products/pomhex.html
Dapone and atovaquone are therapeutic options for PJP prophylaxis in renal transplant recipients. The objective of this study was to evaluate the incidence of anemia in renal transplant recipients receiving these agents. This is an IRB-approved, retrospective analysis of adult renal transplant recipients who received either dapsone or atovaquone. The primary endpoint was the change in hemoglobin within 90days of drug initiation. Other endpoints of interest included incidence and management of anemia at multiple time points post-transplan
Like
Comment
Share
